MOTS-c Peptide: Study Models, Terminology and Open Questions

MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame inside the mitochondrial 12S rRNA gene, first reported in 2015. Most of what is published about it comes from cell and mouse models, with a small set of human measurement studies.

This article is a literature-led overview of MOTS-c as it appears in the published research record. It covers the sequence and its unusual origin, the study models behind the main papers, the measurement problem, its regulatory and anti-doping status, and the questions still open. For wider background on signaling research, see mechanism and pathways.

This is background context for researchers evaluating reference material. Nothing here describes or recommends any application outside a laboratory setting.

Sequence, origin and naming

MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. Lee and colleagues (2015) reported a short open reading frame within the mitochondrial 12S rRNA gene that encodes the peptide, in a paper built on cell culture and mouse experiments. The UniProt reference entry lists the human sequence as MRWQEMGYIFYPRKLR, 16 residues long, with a mass of about 2,175 daltons, under the gene name MT-RNR1.

The name records where the sequence sits in the genome. It does not describe a function. A similar gap between a compound’s name and its evidence runs through the DSIP literature.

More terms from the source papers are collected in glossary and reference.

Where it is translated

The origin creates a genuine puzzle. Mitochondria read their own DNA with a genetic code that differs slightly from the one used in the rest of the cell. Lee and colleagues stated that MOTS-c translation must occur in the cytoplasm using the standard code, because the mitochondrial code would produce tandem start and stop codons at that position. They also searched nuclear DNA for mitochondrial-like copies of the sequence, known as NUMTs, and reported that none encoded a peptide fully matching MOTS-c. Rats carry no NUMT copies of the sequence, which the authors used to argue that mitochondrial DNA is its exclusive source in that species.

Study models and what they examined

Four papers show the range of models behind the core literature.

Cell and mouse study (2015)

The founding paper used human and rat cell lines alongside CD-1 and C57BL/6 mice. At the cellular level, the authors reported that MOTS-c inhibited the folate cycle and the de novo purine synthesis tied to it, leading to activation of AMPK, an enzyme that senses cellular energy status. In mice on a high-fat diet and in older mice, they examined insulin sensitivity and weight gain, and they identified skeletal muscle as the apparent primary target tissue. These are animal findings from one research group.

Cell culture study of nuclear translocation (2018)

In a cell culture study using HEK293, HepG2 and C2C12 cells, Kim, Son, Benayoun and Lee (2018) reported that MOTS-c moved to the nucleus within 30 minutes of metabolic stress induced by glucose restriction, serum deprivation or oxidative stress, in an AMPK-dependent manner. In the nucleus, they reported binding to DNA regions containing antioxidant response elements and interaction with the transcription factor NRF2. Based on mutagenesis experiments, the authors suggested that nuclear entry may require interaction with other proteins.

Mouse study with a human exercise arm (2021)

Reynolds and colleagues (2021) combined mouse experiments at 2, 12 and 22 months of age with a small human study. The human arm enrolled 10 sedentary, healthy young men who completed one session of cycling intervals. Muscle biopsies and plasma were sampled at baseline, midway, immediately after and 4 hours after the session. The authors reported that muscle MOTS-c measured by western blot rose about 11.9-fold after exercise, and plasma levels measured by ELISA rose about 1.6-fold during exercise and 1.5-fold after it.

Observational human study (2018)

In a cross-sectional observational study, Qin and colleagues (2018) measured circulating MOTS-c by ELISA in aortic plasma from 40 adults undergoing coronary angiography and endothelial function testing, split evenly by the result of that testing, alongside separate rodent tissue experiments. The authors reported lower MOTS-c levels in the group with endothelial dysfunction. The design shows an association at one time point. It cannot show direction or cause, and it relied on the immunoassay approach examined in the next section.

Single papers are summarized in more depth under study summaries.

The measurement problem

Every human finding above depends on measuring small amounts of a 16-residue peptide in blood or tissue. The literature shows how hard that is.

Knoop, Thomas and Thevis (2019) developed and validated a liquid chromatography mass spectrometry method for MOTS-c in plasma, built for doping control, with a lower limit of detection of 100 pg/mL. They compared it with a commercially available ELISA. In a reference group of 20 healthy adults, the ELISA returned endogenous levels of 45.9 to 218.5 ng/mL, and the mass spectrometry method could not confirm those levels. The authors reported considerable differences between the two approaches.

The same distinction between a signal and a confirmed identity applies to reference material on the bench, covered in orthogonal peptide identification. Knoop and colleagues also characterized four in vitro metabolites and two oxidation products. The sequence contains two methionines and a tryptophan, residues commonly prone to oxidation, which is why storage conditions deserve attention. Published stability data sits under handling and storage.

Regulatory and anti-doping status

MOTS-c is not an approved drug in the United States. The U.S. Anti-Doping Agency states that it is not approved by the Food and Drug Administration for use in humans.

In sport, the position is settled. USADA notes that MOTS-c is prohibited at all times under section 4.4, Metabolic Modulators, of the World Anti-Doping Agency Prohibited List. The mass spectrometry method described above was developed for exactly that detection purpose.

None of this changes what research material may be used for. Under federal regulation, an article’s intended use is judged by the objective intent of the persons legally responsible for its labeling, shown by their statements, the article’s design or composition, and the circumstances of its distribution. A supplier’s Research Use Only policy states the only intended use of the material.

What the evidence cannot yet tell you

• Most findings are preclinical. The mechanistic and whole-animal work is in cell lines and mice. Results in those models do not establish what happens in people.
• The founding work is concentrated. The central papers share authors from a connected group of laboratories. Replication by unrelated groups is still thin.
• Human data measure the endogenous peptide. The exercise and coronary studies measured naturally occurring MOTS-c. Neither tested synthetic peptide.
• Human samples are small. The exercise arm enrolled 10 people and the coronary comparison 40.
• Circulating levels are unsettled. Immunoassay and mass spectrometry disagree, so absolute concentrations are not yet reliable reference values.

Documenting MOTS-c reference material

Because MOTS-c is short, sequence-defined and prone to oxidation, the identity record matters more than a single purity figure. Why a chromatographic percentage alone falls short is covered in peptide impurity thresholds.

• Full sequence stated, MRWQEMGYIFYPRKLR, not only the name
• Observed mass by mass spectrometry, compared with the theoretical mass for that sequence
• Chromatographic method named, with the main peak and impurity summary
• Oxidized forms addressed, or their absence from the method noted
• Net peptide content or counterion, where stated
• Lot number matched across vial, certificate and order record
• Analysis date, storage conditions and retest date

Match the certificate to the vial before relying on any of it, as set out in COA verification and lot traceability. A supplier that publishes its testing methods and laboratory details makes those checks possible, and a lot-matched certificate library lets you confirm the lot number, certificate identifier and test date against your own record.

Frequently asked questions